10-Q: Phio Pharma Reports Q2 Loss, Advances Cancer Drug

Phio Pharmaceuticals Corp. reported a net loss of $2.17 million for Q2 2025, while advancing its lead cancer therapeutic PH-762 in clinical trials and securing significant capital.

Summary

• Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics using its proprietary INTASYL technology.
• The company reported a net loss of $2.17 million for the three months ended June 30, 2025, compared to a net loss of $1.85 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $3.94 million, a slight improvement from $4.00 million in the prior year period.
• Research and development expenses increased by 24% to $1.07 million for the three months ended June 30, 2025, primarily due to higher patient enrollment and consultant fees.
• General and administrative expenses increased by 18% to $1.24 million for the three months ended June 30, 2025, driven by increased salary-related costs for new hires.
• Cash and cash equivalents significantly increased to $10.78 million as of June 30, 2025, from $5.38 million at December 31, 2024, primarily due to recent financing activities.
• The company successfully completed multiple registered direct offerings and private placements in December 2024 and January 2025, raising substantial net proceeds.
• The lead product candidate, PH-762, is in a U.S. multi-center Phase 1b clinical trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
• The Safety Monitoring Committee (SMC) recommended dose escalation to the fifth cohort for PH-762 on June 25, 2025, with enrollment expected to complete in Q3 2025.
• Early clinical data for PH-762 in 15 patients showed 5 pathologic complete responses (100% tumor clearance) in cSCC patients, and partial responses in one cSCC and one Merkel cell patient.
• PH-762 has been well tolerated with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.
• The collaboration agreement with AgonOx, Inc. for PH-762 treated DP TIL was terminated in May 2024, settling all future financial obligations.
• Development of PH-894, an INTASYL compound targeting BRD4, has completed IND-enabling studies, but its IND submission has been deferred to prioritize PH-762.
• The company's current cash resources are expected to fund operations into the second quarter of 2026.
• The company continues to report recurring losses and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern without additional funding.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and faces a going concern warning, the successful capital raises have significantly improved its liquidity, extending the cash runway. More importantly, the clinical trial for PH-762 shows promising early efficacy signals and a good safety profile, with continued dose escalation. The deferral of PH-894 is a minor setback but reflects a strategic focus. The overall picture is one of a high-risk, high-reward biotech making clinical progress and managing its financial needs, albeit with substantial dilution.

Positives

• Cash and cash equivalents increased significantly to $10.78 million at June 30, 2025, from $5.38 million at December 31, 2024, providing extended liquidity.
• Successful completion of multiple equity and warrant offerings in December 2024 and January 2025, generating approximately $6.7 million in net proceeds.
• Positive clinical progress for PH-762, with the Safety Monitoring Committee recommending dose escalation to the fifth cohort in the Phase 1b trial.
• Encouraging early efficacy signals for PH-762, including 5 pathologic complete responses (100% tumor clearance) in cutaneous squamous cell carcinoma patients.
• PH-762 demonstrated a favorable safety profile, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.
• The company is currently in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, with $10.1 million reported at June 30, 2025.

Negatives

• Reported recurring losses from operations since inception, with a net loss of $2.17 million for Q2 2025 and $3.94 million for the six months ended June 30, 2025.
• Continued negative operating cash flows, with $3.82 million used in operating activities for the six months ended June 30, 2025.
• The company explicitly states that its current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the financial statement release date, raising substantial doubt about its ability to continue as a going concern.
• The IND submission for PH-894 has been deferred, indicating a delay in advancing this pipeline candidate.
• The termination of the AgonOx collaboration means the company will not receive future development milestones or royalty payments from AgonOx's DP TIL technology licensing.

Risks

• Dependence on the success of the unproven INTASYL technology and its product candidates, which may never lead to approved and marketable products.
• Product candidates are in an early stage of development, facing potential failures, significant delays, or inability to advance in clinical development.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could negatively impact business operations and regulatory approvals.
• Potential for delays or difficulties in identifying and enrolling subjects in clinical trials, which could delay data generation and regulatory approvals.
• Topline data from clinical trials may not accurately reflect or may materially differ from complete results.
• Reliance on third parties for the manufacture of clinical supply for product candidates.
• Risk of computer system failures, cyberattacks, or cybersecurity deficiencies impacting business and operations.
• Dependence on owned patents and licensed technologies; failure to maintain or loss of rights could harm product development.
• Requirement for substantial additional funds to complete research and development activities.
• Future financing efforts may involve the issuance of dilutive debt or equity, adversely affecting stockholders.
• Inability to maintain compliance with Nasdaq Capital Market listing requirements, specifically the $2.5 million stockholders' equity and $1.00 minimum bid price rules, which could lead to delisting.
• Changes in U.S. and international trade policies could adversely impact business and operating results, including product supply disruption and increased costs.

Future Outlook

The company expects to continue incurring substantial operating losses for several years as it develops product candidates and seeks marketing approval. It anticipates needing additional funding to sustain future operations beyond the second quarter of 2026, with no assurance that such capital will be available on favorable terms or at all. The scope, progress, and costs of clinical trials for PH-762, the internal funding of PH-894, and the ability to enter into strategic arrangements will influence future capital requirements.

Management Comments

• "We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future."
• "Expense reductions have been redirected to funding the Phase 1b clinical trial with PH-762."
• "We believe these data further support the potential for PH-762 to provide a strong local immune response without the dose immune-related adverse effects seen with systemic antibody therapy."
• "PH-762 has been well tolerated in all enrolled patients in each escalating dose cohort."
• "As a result of the reprioritization to advance our clinical trial with PH-762 in the U.S., we have elected to defer the IND submission for PH-894."
• "Our current cash resources may not provide sufficient capital to fund operations for at least the next 12 months from the date of the release of these condensed consolidated financial statements."
• "Our continuation as a going concern depends upon our ability to raise additional capital through equity offerings, debt offerings and/or strategic opportunities to fund our operations."

Industry Context

Phio Pharmaceuticals operates in the highly competitive and capital-intensive immuno-oncology sector of the biopharmaceutical industry. Its focus on INTASYL self-delivering siRNA technology for immune cell modulation positions it within the innovative gene therapy and targeted therapeutics space. The company's strategy to develop treatments that precisely target proteins inhibiting the body's cancer fight, without complex delivery systems, aims to differentiate it from traditional small molecule or antibody therapies. The deferral of PH-894 IND submission to prioritize PH-762 reflects a common strategy in early-stage biotech to focus limited resources on the most advanced or promising candidate, a necessary trade-off given the high costs and risks of drug development. The recurring need for capital raises is typical for clinical-stage biotechs that have not yet generated product revenue.

Comparison to Industry Standards

• The company's cash burn rate, while significant, is typical for a clinical-stage biopharmaceutical company actively conducting Phase 1b trials. Comparable early-stage oncology companies often operate with similar or higher R&D expenses depending on the number and stage of their clinical programs.
• The reported net losses and negative operating cash flows are standard for companies in this development phase, as substantial investment is required before potential product commercialization.
• The reliance on equity financing and warrant exercises for liquidity is a common funding mechanism for pre-revenue biotech firms, though it leads to significant shareholder dilution, as evidenced by the substantial increase in common shares outstanding.
• The clinical trial progress for PH-762, particularly the observed pathologic complete responses in cSCC, is a positive signal for an early-stage asset. While direct comparisons to specific competitor projects are not detailed in the filing, such early response rates can be competitive within the immuno-oncology landscape for novel mechanisms of action.
• The explicit 'going concern' disclosure is a standard regulatory requirement for companies with recurring losses and limited cash runway, and is not uncommon for small, clinical-stage biotechs, reflecting the inherent financial risks of the industry rather than necessarily a worse-than-average performance compared to peers in similar situations.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any actual or threatened material legal proceedings.

Stakeholder Impact

• **Shareholders**: Significant dilution from multiple equity and warrant offerings, but increased liquidity reduces immediate going concern risk. Clinical progress of PH-762 could positively impact long-term value if successful, but early stage development carries high risk.
• **Employees**: Headcount reduction by greater than 50% in discovery research personnel since January 2024 due to cost rationalization. Robert Infarinato's separation indicates ongoing management adjustments.
• **Customers (Future Patients)**: Continued development of PH-762 offers potential new treatment options for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma patients, with promising early safety and efficacy data.
• **Suppliers/Creditors**: Improved cash position from recent financings enhances the company's ability to meet short-term obligations, but the 'going concern' warning indicates continued reliance on future funding.

Next Steps

• Complete enrollment in the PH-762 Phase 1b clinical trial in the third quarter of 2025.
• Continue to assess cash and cash equivalents and future funding requirements.
• Seek additional funding through equity offerings, debt offerings, and/or strategic opportunities to sustain future operations.
• Potentially advance PH-894 to IND submission at a later date, following reprioritization.

Key Dates

Recommendation

Phio Pharmaceuticals is a highly speculative investment given its clinical-stage nature, recurring losses, and explicit 'going concern' warning. However, the recent successful capital raises have significantly bolstered its cash position, extending its runway into Q2 2026, which is crucial for its survival. The early Phase 1b clinical data for PH-762, particularly the observed complete responses and favorable safety profile, are promising and represent a key value driver. While the deferral of PH-894 is a minor negative, the strategic focus on PH-762 is understandable. For a seasoned investor, the stock is a 'hold' as the company has secured near-term funding and shown positive, albeit early, clinical signals. The high risk associated with clinical development and the need for future capital raises prevent a 'buy' recommendation, but the recent progress warrants not recommending a 'sell' at this juncture.

Keywords

Immuno-oncology, Biopharmaceutical, Clinical stage, INTASYL, siRNA, PH-762, PD-1, Cancer treatment, Clinical trial, Phase 1b, Cutaneous squamous cell carcinoma, Melanoma, Merkel cell carcinoma, PH-894, BRD4, Oncology, Biotech, SEC filing, 10-Q, Capital raise, Warrants, Nasdaq